Three technologies that will shape biotech in 2026

Recently, embryo scoring has evolved. Labs can pinch off a couple of cells from an embryo, look at its DNA, and screen for some genetic diseases. That list of diseases is increasing. And now some companies are taking things even further, offering prospective parents the opportunity to select embryos for features like height, eye color, and even IQ.

This is controversial for lots of reasons. For a start, there are many, many factors that contribute to complex traits like IQ (a score that doesn’t capture all aspects of intelligence at any rate). We don’t have a perfect understanding of those factors, or how selecting for one trait might influence another.

Some critics warn of eugenics. And others note that whichever embryo you end up choosing, you can’t control exactly how your baby will turn out (and why should you?!). Still, that hasn’t stopped Nucleus, one of the companies offering these services, from inviting potential customers to have their “best baby.” Read more here.

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.